© Georg Thieme Verlag Stuttgart · New York
MRI Evaluation of Aseptic Osteonecrosis in Children over the Course of Hyperbaric Oxygen Therapy
31 December 2000 (online)
Purpose: The study aimed at MRI evaluation of aseptic osteonecrosis (AON) in children over the course of hyperbaric oxygen (HBO) therapy. Material and Methods: Retrospective analysis of 72 MRI studies in 20 children presenting with AON during chemotherapy. Two groups were differentiated: Gr. I (n = 8) was treated exclusively with relief of weightbearing structures, Gr. II (n = 12) was additionally treated with HBO therapy. The MRI examinations were evaluated by a point-score system (1 - 6 points) by two radiologists. Results: Gr. II initially showed more severe findings (average score: 3.4) in comparison to Gr. I (average score: 2.65). During the follow-up time period the average scores rose to 3.2 score-points in Gr. I and 4.1 points in Gr. II. No statistically significant difference was evident between the two groups in the course of AON. Conclusion: The majority of chemotherapy associated AON which initially present with advanced findings show a progression in MRI over their further course. HBO therapy in addition to the relief of affected weightbearing structures statistically shows no significant improvement in MRI morphology during the course of the treatment.
MRI - Hyperbaric Oxygenation - Chemotherapy - Osteonecrosis
- 1 Janka-Schaub G E, Harms D, Goebel U. et al .Randomized comparison of rotational chemotherapy in high-risk acute lymphoblastic leukaemia of childhood - follow up after 9 years. CoALL study group. Eur J Pediatr 1996: 640-648
- 2 Bömelburg T, von Lengerke H J, Ritter J. Aseptic osteonecrosis in treatment of acute leukaemias. Eur J Pediatr. 1989; 149 20-23
- 3 Ojala A E, Paakko E, Lanning P, Lanning M. Osteonecrosis during treatment of childhood acute lymphoblastic leukaemia: a prospective MRI study. Med Pediatr Oncol . 1999; 32 11-17
- 4 Murphy R G, Greenberg M L. Osteonecrosis in pediatric patients with acute lymphoblastic leukaemia. Cancer. 1990; 65 1717-1721
- 5 Chang C C, Greenspan A, Gershwin M E. Osteonecrosis: current perspectives on pathogenesis and treatment. Semin Arthritis Rheum. 1993; 23 47-69
- 6 Waisman D, Shupak A, Weisz G, Melamed Y. Hyperbaric oxygen therapy in the pediatric patient: the experience of the Israel Naval Medical Institute. Pediatrics. 1998; 102 E53
- 7 Kataoka Y, Hasegawa Y, Iwata H. et al . Effect of hyperbaric oxygenation on femoral head osteonecrosis in spontaneously hypertensive rats. Acta Orthop Scand. 1992; 63 527-530
- 8 Levin D, Norman D, Zinman C. et al . Treatment of experimental avascular necrosis of the femoral head with hyperbaric oxygen in rats: histological evaluation of the femoral heads during the early phase of the reparative process. Exp Mol Pathol. 1999; 67 99-108
- 9 Ashamalla H L, Thom S R, Goldwein J W. Hyperbaric oxygen therapy for the treatment of radiation-induced sequelae in children. The University of Pennsylvania experience. Cancer. 1996; 77 2407-2412
- 10 Wattel F, Mathieu D eds.). Protocol of the 1st European Consensus Conference on Hyperbaric Medicine.
Lille, France 19. 9. - 21. 9. 94, Reports and Recommendations.
- 11 Thornton M J, O'Sullivan G, Williams M P, Hughes P. Avascular necrosis of bone following an intensified chemotherapy regimen including high dose steroids. Clin Radiol. 1997; 52 607-612
- 12 Mitchell D G, Rao V M, Dalinka M K. et al . Femoral head avascular necrosis: correlation of MR imaging, radiographic staging, radionuclide imaging, and clinical findings. Radiology. 1987; 162 709-715
- 13 Engelbrecht V, Scherer A, Bruder M, Körholz D, Mödder U. Kernspintomographie von aseptischen Osteonekrosen bei Kindern und Jugendlichen mit einer akuten lymphoblastischen Leukämie. Fortschr Röntgenstr. 2000; 172 336-341
- 14 Marx R E, Ehler W J, Tayapongsak P, Pierce L W. Relationship of oxygen dose to angiogenesis induction in irradiated tissue. Am J Surg. 1990; 16 519-524
Axel Scherer, , MD
Institute of Diagnostic Radiology Heinrich-Heine University
Phone: + 49- 211- 8 117 752
Fax: + 49- 211- 8 116 299